Roivant Sciences

Roivant Sciences

Biotechnologie

New York, New York 26.308 Follower:innen

Reinventing Biopharma

Info

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Website
http://www.roivant.com
Branche
Biotechnologie
Größe
201–500 Beschäftigte
Hauptsitz
New York, New York
Art
Kapitalgesellschaft (AG, GmbH, UG etc.)
Gegründet
2014

Orte

Beschäftigte von Roivant Sciences

Updates

Ähnliche Seiten

Finanzierung